jshort, Author at Sanford Burnham Prebys - Page 5 of 13
Institute News

The Collaboration 4 Cure Alzheimer’s research awards announced at SBP

Authorsgammon
Date

October 29, 2015

On October 28, Mayor Kevin Faulconer, County Supervisor Diane Jacob, San Diego philanthropist Darlene Shiley, and Mary Ball, president and CEO of the Alzheimer’s Association San Diego, came to SBP to announce the recipients of research awards from San Diego’s Dementia Drug Discovery Collaborative Program, “Collaboration 4 Cure (C4C).” The awards are part of an innovative program to harvest the best research ideas toward effective treatment of Alzheimer’s disease.

Eight world-class researchers were selected by C4C to pursue promising drug discovery projects. They will be given state-of-the-art equipment, resources and expertise at SBP’s Conrad Prebys Center for Chemical Genomics (Prebys Center) and The Scripps Research Institute to search for “small molecule” chemicals that can alter changes in the brain observed in Alzheimer’s disease, potentially restoring brain health to patients.

The research award recipients and their projects include:

  • Huaxi Hu, PhD, (SBP), will search for chemicals that can activate microglia cells, which protect neurons from inflammation and remove damaged cells.
  • Elena Pasquale, PhD, (SBP), funded to search for molecules that that prevent protein aggregation that form amyloid beta plaques.
  • Lutz Tautz, PhD, (SBP), will screen for molecules that reduce levels of an enzyme thought to inhibit memory formation in Alzheimer’s patients.
  • Yunwu Zhang, PhD, (SBP), will search for compounds that target apotosin, a protein thought to damage neurons.
  • Albert La Spada, MD, PhD (UCSD), will screen for molecules that increase the activity of lysosomes, packets of enzymes with protein-clearing powers.
  • Mathew Pearn, MD, (UCSD), funded to examine protein-bearing cellular structures called endosomes from growing too large and killing neurons.
  • Subhojit Roy, PhD, (UCSD), will seek ways to separate precursor proteins from the enzymes that turn them into amyloid beta.
  • Steve L. Wagner, PhD, (UCSD), will search for a way to mute the side effects of gamma secretase inhibitors, which can disrupt the amyloid formation process.

“SBP is proud to be part of C4C. San Diego is home to some of the best neuroscientists in the world, and with our advanced screening and drug discovery capabilities at the Prebys Center, we hope to quickly advance research to prevent, treat, and even cure this terrible disease,” said Michael Jackson, PhD, senior vice president of Drug Discovery and Development at SBP.

Initial funds for the launch of C4C, totaling nearly $500,000, were obtained through the generosity of Darlene Shiley and others involved with the initiative. With a five-year funding goal of $7 million, all funds will be raised through local philanthropy, and restricted to projects from researchers at San Diego-based institutions.

Alzheimer’s disease is the third-leading cause of death in the San Diego region.

To view the KUSI newscast of the event, click here

Institute News

SBP’s 37th Annual Symposium is around the corner

Authorsgammon
Date

October 21, 2015

This year’s Annual SBP Symposium theme is Aging and Regeneration. The line-up of distinguished speakers will cover topics from stem cell renewal, selective autophagy, and drugs that stop the aging process. Continue reading “SBP’s 37th Annual Symposium is around the corner”

Institute News

‘Big Data’ used to identify new cancer driver genes

Authorsgammon
Date

October 20, 2015

In a collaborative study led by Sanford Burnham Prebys Medical Discovery Institute (SBP), researchers have combined two publicly available ‘omics’ databases to create a new catalogue of ‘cancer drivers’. Cancer drivers are genes that when altered, are responsible for cancer progression. The researchers used cancer mutation and protein structure databases to identify mutations in patient tumors that alter normal protein-protein interaction (PPI) interfaces. The study, published today in PLoS Computational Biology, identified more than 100 novel cancer driver genes and helps explain how tumors driven by the same gene may lead to different patient outcomes.

“This is the first time that three-dimensional protein features, such as PPIs, have been used to identify driver genes across large cancer datasets,” said lead author Eduard Porta-Pardo, PhD, a postdoctoral fellow at SBP. “We found 71 interfaces in proteins previously unrecognized as cancer drivers, representing potential new cancer predictive markers and/or drug targets. Our analysis also identified several driver interfaces in known cancer genes, such as TP53, HRAS, PI3KCA and EGFR, proving that our method can find relevant cancer driver genes and that alterations in protein interfaces are a common pathogenic mechanism of cancer.”

Cancer is caused by the accumulation of mutations to DNA. Until now, scientists have focused on finding alterations in individual genes and cell pathways that can lead to cancer. But the recent push by the National Institutes of Health (NIH) to encourage data sharing has led to an era of unprecedented ability to systematically analyze large scale genomic, clinical, and molecular data to better explain and predict patient outcomes, as well as finding new drug targets to prevent, treat, and potentially cure cancer.

“For this study we used an extended version of e-Driver, our proprietary computational method of identifying protein regions that drive cancer. We integrated tumor data from almost 6,000 patients in The Cancer Genome Atlas (TCGA) with more than 18,000 three-dimensional protein structures from the Protein Data Bank (PDB),” said Adam Godzik, PhD, director of the Bioinformatics and Structural Biology Program at SBP. “The algorithm analyzes whether structural alterations of PPI interfaces are enriched in cancer mutations, and can therefore identify candidate driver genes.”

“Genes are not monolithic black boxes. They have different regions that code for distinct protein domains that are usually responsible for different functions. It’s possible that a given protein only acts as a cancer driver when a specific region of the protein is mutated,” Godzik explained. “Our method helps identify novel cancer driver genes and propose molecular hypotheses to explain how tumors apparently driven by the same gene have different behaviors, including patient outcomes.”

“Interestingly, we identified some potential cancer drivers that are involved in the immune system. With the growing appreciation of the importance of the immune system in cancer progression, the immunity genes we identified in this study provide new insight regarding which interactions may be most affected,” Godzik added.

The study was performed in collaboration with the European Bioinformatics Institute (UK), Centro de Investigación Principe Felipe (Spain), and CIBER de Enfermedades Raras (Spain).

Institute News

How proteins age

Authorsgammon
Date

October 19, 2015

SBP researchers and colleagues discover a mechanism that regulates the aging and abundance of secreted proteins.

Physiological processes in the body are in large part determined by the composition of secreted proteins found in the circulatory systems, including the blood. Each of the hundreds of proteins in the blood has a specific life span that determines its unique range of abundance. In fact, measurements of their quantities and activities contribute to many clinical diagnoses. However, the way in which normal protein concentrations in the blood are determined and maintained has been a mystery for decades.

Biomedical scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC Santa Barbara (UCSB) have now discovered a mechanism by which secreted proteins age and turnover at the end of their life spans. Their findings, which shed light on a crucial aspect of health and disease, appear today in the Proceedings of the National Academy of Sciences (PNAS).

“This is a fundamental advance that is broadly applicable and provides an understanding of how secreted proteins, which are involved in many important physiological processes, normally undergo molecular aging and turnover,” said senior author Jamey Marth, PhD, professor in SBP’s NCI-designated Cancer Center.

“When a secreted protein is made, it has a useful life span and then it must be degraded — the components are then basically recycled,” added Marth, also director of UCSB’s Center for Nanomedicine and a professor in the campus’s Department of Molecular, Cellular, and Developmental Biology. “We can now see how the regulation and alteration of secreted protein aging and turnover is able to change the composition of the circulatory system and thereby maintain health as well as contribute to various diseases.”

This newly discovered mechanism encompasses multiple factors, including circulating enzymes called glycosidases. These enzymes progressively remodel N-glycans, which are complex structures of monosaccharide sugars linked together and attached to virtually all secreted proteins.

It is the N-glycan structure itself that identifies the protein as nearing the end of its life span. Subsequently, multiple receptors known as lectins — carbohydrate-binding proteins — recognize these aged proteins and eliminate them from circulation.

Marth and colleagues identified more than 600 proteins in the bloodstream that exhibit molecular signs of undergoing this aging and turnover process. Many of these proteins are regulators of proteolysis (the breakdown of proteins), blood coagulation and immunity.

Honing in on individual examples, the researchers were able to track each of them through time and watch the process unfold. “In these studies we further saw that the different life spans of distinct proteins are accounted for by the different rates of aging due to N-glycan remodeling,” said lead author Won Ho Yang, PhD, a postdoctoral associate at SBP and at UCSB’s Center for Nanomedicine.

“Altering this aging and turnover mechanism is the fastest way to change the abundance of a secreted protein, which we increasingly note is occurring at the interface of health and disease,” Marth explained. “In retrospect from published literature and from studies in progress, we can now see how sepsis, diabetes and inflammatory bowel disorders can arise by the targeted acceleration or deceleration of secreted protein aging and turnover.”

“The discovery of this mechanism provides a unique window into disease origins and progression,” Marth added. “It has been known that circulating glycosidase enzyme levels are altered in diseases such as sepsis, diabetes, cancer and various inflammatory conditions. The resulting changes in the composition and function of the circulatory systems, including the blood and lymphatic systems, can now be identified and studied. We are beginning to see previously unknown molecular pathways and connections in the onset and progression of disease.”

Institute News

San Diego is serious about science

Authorsgammon
Date

October 14, 2015

“San Diego’s non-profit research institutions are the backbone of scientific innovation. They are the birthplace of groundbreaking advances in biosciences and translational research that yield life-changing discoveries and therapies.”

2015 Economic Impact of San Diego’s Research Institutions Report San Diego Regional Economic Development Corporation

On Tuesday, October 13, the San Diego Regional Economic Development Corporation released their annual report on the contribution that non-profit research institutions make to the local economy. And what it revealed is what many of us already knew—that San Diego is the most concentrated scientific R&D market in the United States and a global leader in innovation.

The report was generated with the guidance of numerous research institutions, including SBP, Salk Institute for Biological Studies, Scripps Research Institute, J. Craig Venter Institute, and West Health Institute, and is the most comprehensive analysis on San Diego’s research institutions to date.

Here are some of the highlights from the report’s findings that reinforce San Diego as an epicenter of life science research and innovation:

  • Independent research institutions in San Diego receive more NIH research funding and generate more patents than any other metro area of the United States.
  • Research institutions impact 37,000 jobs and have a combined $4.6 billion impact on the region’s gross regional product (GRP) every year.
  • The $4.6 billion economic impact of research institutions equates to 33 U.S. Open Golf Championships, 4 San Diego Convention Centers, 34 San Diego Comic-Cons, or 6 aircraft carriers.
  • Many of the world’s best and brightest scientists perform cutting edge research in San Diego; there are 111 living National Academy of Science members and more than 2,600 postdocs within research institutions alone.

The information in the report will be used to build supporting coalitions with industry leaders, attract investment in the life science sector, and increase funding to make sure that science, technology, engineering and math (STEM) students stay in the area to address the workforce issues that this dynamic sector requires.

 

To read the report click here

Institute News

SBP Collaborates with NIH’s Translational Science Center on pancreatic cancer

Authorsgammon
Date

October 13, 2015

The National Center for Advancing Translational Sciences (NCATS) has initiated a novel collaborative study with Pamela Itkin-Ansari, PhD., to screen for drugs that reprogram pancreatic cancer cells back to a normal, non-threatening phenotype.

The collaboration is based on Itkin-Ansari’s research and development of a screening platform to find drugs that induce the overexpression of E47, a protein that binds to specific DNA sequences, causing cells to differentiate to acinar cells—cells with normal pancreatic cell traits and characteristics.

“I’m delighted to be working with NCATS on a project that may lead to better treatments for pancreatic cancer patients,” said Itkin-Ansari, adjunct professor in the Development, Aging, and Regeneration Program at SBP. “The Center will be screening novel compounds as well as approved drugs that can be repurposed, potentially accelerating the clinical development process due to their known safety profiles and characterized mechanisms.”

The outlook for patients with pancreatic cancer is very poor. Among people diagnosed with the disease, 80 percent are dead within the first year, and 90 percent the year after that. And pancreatic cancer is one of the few cancers for which survival has not improved substantially in 40 years.

One reason pancreatic cancer is so deadly is that there are no good detection tools to diagnose the disease in the early stages, so by the time most patients are diagnosed the cancer has spread to the liver or other areas of the body. Another reason is that there are really no good treatments—response to chemotherapy and radiation is poor.

NCATS was established by the National Institutes of Health (NIH) to transform the translational science process so that new therapies for disease can be delivered to patients faster. For drug discovery collaborations, the Center works with academic investigators that are biology and disease experts that have demonstrated a novel approach, a primary screening platform that they can adapt, and a follow-up critical path for the project.

Dr. Itkin-Ansari pointed out that technical guidance provided by the Conrad Prebys Center for Chemical Genomics at SBP was instrumental in validation of her screening platform. “Their experience in developing high throughput screening assays, such as the one that will be used in this collaboration, is unparalleled in the nonprofit research sector” said Itkin-Ansari.

“NCATS has a history of success in novel therapeutic approaches and I’m hopeful that our collaboration will result in identification of a proof-of-concept compound for advancing studies on reprogramming as an intervention for pancreatic cancer.”

The research will be funded by the Marian and Ralph Falk Medical Research Trust.

Institute News

New STRIVE awards announced

Authorsgammon
Date

October 8, 2015

“The STRIVE award is providing funds that allow us to accelerate the testing of a new hypothesis that connects the microbiome, epigenetics, and colorectal cancer.”        

          –Alex Strongin, PhD professor in the Bioinformatics and Structural Biology Program at SBP. Continue reading “New STRIVE awards announced”

Institute News

She has a 1 in 8 chance of getting breast cancer

Authorsgammon
Date

October 5, 2015

October is Breast Cancer Awareness month, an annual campaign to increase knowledge and awareness of the disease. Have a look at some of the staggering statistics about breast cancer to understand why this is an important cause for so many people. Although tremendous advances have been made, there is still work to be done into the causes, prevention, diagnosis, and treatment of the disease.

Continue reading “She has a 1 in 8 chance of getting breast cancer”

Institute News

2015 Fishman Fund Award recipients honored

Authorsgammon
Date

October 5, 2015

The 2015 Fishman Fund Award recipients were honored at an October 1 gathering of Sanford Burnham Prebys (SBP) supporters that celebrated the enduring legacy of the Institute’s founders, Dr. William and Lillian Fishman.

Continue reading “2015 Fishman Fund Award recipients honored”

Institute News

Meet the “drug hunter”

Authorsgammon
Date

October 1, 2015

SBP’s newly recruited vice president of Discovery Medicine, Muhammad Al-Hajj, PhD, is leading the charge across a bridge connecting our research discoveries with resources to develop new therapies for cancer patients. His job requires him to have one foot in the research labs and one foot out dancing with commercial pharma, biotech, and venture capital companies willing to fund the development of new cancer drugs.

Continue reading “Meet the “drug hunter””